Related Experiment Video
Updated: Jul 15, 2026

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
Published on: December 20, 2017
Alpha-galactosidase A in vascular disease
Peter F Bodary1, James A Shayman, Daniel T Eitzman
1Department of Nutrition and Food Science, Wayne State University, Detroit MI 48202, USA.
Insights
Fabry disease, caused by alpha-galactosidase A deficiency, leads to harmful glycosphingolipid buildup. This review explores how GLA deficiency may contribute to premature macrovascular events like stroke.
Area of Science:
- Biochemistry
- Vascular Biology
- Genetics
Background:
- Fabry disease results from alpha-galactosidase A (GLA) deficiency, causing glycosphingolipid accumulation.
- This accumulation leads to multiorgan pathology, including microvascular complications.
- Premature macrovascular events like stroke are also associated with GLA deficiency.
Purpose of the Study:
- To review potential mechanisms linking GLA deficiency to macrovascular disease.
- To explore the role of glycosphingolipid metabolism abnormalities in vascular complications.
- To discuss findings from a mouse model of GLA deficiency.
Main Methods:
- Literature review of studies on GLA deficiency and vascular disease.
- Analysis of data from a mouse model of alpha-galactosidase A deficiency.
- Investigation of glycosphingolipid metabolism pathways.
Main Results:
- GLA deficiency contributes to vascular pathology through glycosphingolipid accumulation.
- Mechanisms linking GLA deficiency to macrovascular events require further elucidation.
- Mouse models provide insights into GLA's role in vascular complications.
Conclusions:
- GLA deficiency is implicated in both microvascular and macrovascular disease.
- Understanding these pathways is crucial for managing Fabry disease complications.
- Further research is needed to fully clarify GLA's impact on the vasculature.
Abstract:
Deficiency of alpha-galactosidase A (GLA) (Fabry disease) leads to the accumulation of glycosphingolipids in the vasculature leading to multiorgan pathology. In addition to well-described microvascular disease, deficiency of GLA is also characterized by premature macrovascular events such as stroke and possibly myocardial infarction. The mechanisms by which GLA may influence macrovascular disease are unclear. A mouse model of GLA deficiency has facilitated the study of glycosphingolipid metabolism abnormalities on macrovascular end points. This review addresses some of the potential pathways by which GLA deficiency may contribute to vascular complications.
Related Concept Videos
Glucose Transporters
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are typically...
Proteoglycans

